Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Myelodysplastic Syndromes 24Leukemia, Myeloid, Acute 14Leukemia, Myelomonocytic, Chronic 7Leukemia 6Polycythemia Vera 3Anemia 3Primary Myelofibrosis 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Recurrence 1Preleukemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hematologic Diseases 1GATA2 Deficiency 1

Interventions

fludarabine phosphate 29ruxolitinib 28Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 25Busulfan 21Tacrolimus 16Whole-Body Irradiation 15Mycophenolic Acid 14Methotrexate 13Cyclosporine 12Hydroxyurea 11Antilymphocyte Serum 11Aspirin 9fludarabine 8Filgrastim 8Melphalan 7Etoposide 7Decitabine 7peginterferon alfa-2a 6Imatinib Mesylate 6Cytarabine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6givinostat hydrochloride 5givinostat 5Radiotherapy 5Prednisone 5Carboplatin 5Biopsy 5Topotecan 4Thiotepa 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Polycythemia Vera × Lenalidomide × Myeloid × Clear all
NCT01375140 2025-06-08

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Completed
31 enrolled 8 charts
Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Incyte Corporation

Phase 3 Completed
222 enrolled 21 charts
Myeloid

Polycythemia Vera

NCT00227591 2014-05-21

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

National Cancer Institute (NCI)

Phase 2 Completed
48 enrolled 7 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡